Lyrica Tapering Guide
pregabalin
Boxed Warning
Respiratory depression risk when used with CNS depressants, particularly opioids. Increased risk of suicidal thoughts and behavior (anticonvulsant class warning).
Overview
Pregabalin is a gabapentinoid approved for neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), fibromyalgia, partial-onset seizures (adjunctive), and spinal cord injury neuropathic pain. It is a Schedule V controlled substance due to abuse potential.
25mg, 50mg, 75mg, 150mg, 300mg
Capsules: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg; Oral solution: 20mg/mL; Extended-release tablets (Lyrica CR): 82.5mg, 165mg, 330mg
Category C (risk cannot be ruled out)
Mechanism of Action
Binds potently to the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Similar mechanism to gabapentin but with 6-fold higher binding affinity. Does not bind GABA receptors.
Taper Notes
Linear, dose-proportional pharmacokinetics (unlike gabapentin) with ≥90% bioavailability. Short half-life (~6 hours) requires slow taper. Capsules can be opened for aqueous titration; oral solution (20 mg/mL) is also available.
Maudsley Deprescribing Guidance
Linear kinetics simplify dose calculation, but short half-life still warrants gradual reductions (~10% per step). Oral solution (20 mg/mL) or weighed capsule contents support sub-mg increments. Schedule V status reflects misuse potential — assess before discontinuation.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Opioids — increased risk of respiratory depression and sedation
- CNS depressants (benzodiazepines, alcohol, barbiturates) — additive sedation and respiratory depression
- ACE inhibitors — pregabalin may increase risk of angioedema
Food Interactions
- Food reduces peak concentration but does not affect total absorption
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to pregabalin (angioedema and hypersensitivity reactions reported)
Toxicity
Dizziness and somnolence most common. Respiratory depression with CNS depressants/opioids. Physical dependence with chronic use. Euphoria/misuse potential (Schedule V). Suicidal ideation (anticonvulsant class warning). Angioedema rarely reported.
Pharmacokinetics
ADME Profile
Rapidly absorbed with linear, dose-proportional pharmacokinetics (unlike gabapentin). Bioavailability ≥90%. Tmax ~1.5 hours. Food decreases Cmax by ~25% and delays Tmax but does not reduce total absorption.
~0.5 L/kg
Negligible metabolism in humans (<2% of dose). No CYP involvement. N-methylated metabolite is the only identified metabolite.
Renal (~90% excreted unchanged). Clearance proportional to creatinine clearance.
Not significantly bound to plasma proteins
~67–80 mL/min (renal clearance)
Build Lyrica taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds